RAK-GOV-MEDIA-OFFICE
12.3.2024 14:33:29 CET | Business Wire | Press release
Steeped in 7,000 years of history, the UAE’s ‘Nature Emirate’ Ras Al Khaimah is undergoing an unprecedented period of economic growth, with tourism, real estate and sustainability taking center stage. Within this dynamic ecosystem, Ras Al Khaimah Art has flourished to become the Emirate’s landmark celebration of culture and the arts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312427377/en/
Featuring works from 107 local and international artists and welcoming 45,000 visitors from around the world, Ras Al Khaimah Art 2024 has successfully concluded its 12th edition at the restored Al Jazeera Al Hamra Heritage Village. Launching as a three-day art exhibition in 2013, Ras Al Khaimah Art has evolved into a month-long annual event and the UAE’s largest outdoor art festival, showcasing Ras Al Khaimah’s vibrant cultural heritage and reflecting the Emirate’s unprecedented cross-sector economic growth. (Photo: AETOSWire)
Inspired by the vision of H.H. Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, the festival was conceived to showcase the Emirate’s artistic talent and foster cultural exchange. Launching at Ras Al Khaimah’s National Museum in 2013 as a three-day exhibition, Ras Al Khaimah Art has evolved into a month-long annual event, welcoming 106 local and international artists from 35 countries in 2024, alongside 45,000 visitors.
Vision & Teamwork
Founding Executive Director of the Al Qasimi Foundation and Ras Al Khaimah Art organiser, Dr. Natasha Ridge acknowledged the event’s potential early on and explored avenues for expansion. During a visit to La Gacilly in France, she encountered a village transformed into an outdoor art gallery and envisioned a similar concept for Ras Al Khaimah Art: “I knew the perfect place.”
Listed on UNESCO’s tentative list of World Heritage Sites, Al Jazeera Al Hamra Heritage Village is the UAE’s last-surviving pearl-fishing village, representing centuries of architecture, trade and culture. Encompassing a fort, watchtowers, a mosque, souq and traditional dwellings, the magical site is defined by a labyrinth of stone alleyways and today, by Ras Al Khaimah Art.
“It’s not just an art festival, it’s also a historical site, which attracts a much wider audience,” says Dr. Ridge.
Ras Al Khaimah Art’s repertoire has expanded to include a range of artistic expressions, from workshops and film screenings to live performances and an art exploration program. “Last year, we saw 1000 students participate in workshops and tours. By connecting our youth with history and culture, we adopt a sustainable approach to the arts,” says Dr. Ridge.
Cultivating Global Connections
Ras Al Khaimah Art plays a pivotal role in promoting Ras Al Khaimah as a cultural destination. By providing a platform for local artists alongside international counterparts, Ras Al Khaimah Art also contributes to the cultural and economic progress of the UAE.
Read more: www.rakart.ae/2024-festival
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312427377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom